New treatment approaches in renal cell carcinoma

Gaetano Facchini, Francesco Perri, Michele Caraglia, Carmela Pisano, Stefano Striano, Luigi Marra, Francesco Fiore, Pasquale Aprea, Sandro Pignata, Rosario Vincenzo Iaffaioli

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Metastatic renal cell carcinoma (RCC) is notoriously chemoresistant; up until recently, immunotherapy (in particular interferon-a) has represented the treatment of choice. The understanding of the biology of RCC has resulted in the development of targeted therapies. In particular, multikinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib), antivascular endothelial growth factor agents (bevacizumab), and mammalian target of rapamycin inhibitors (temsirolimus, everolimus) now have a role in the approach to different subsets of RCC. Sunitinib is indicated for the first-line therapy of metastatic RCC as a consequence of a positive phase III trial versus interferon-α; sorafenib is now registered for the second-line treatment of RCC, which was earlier treated with cytokine as a consequence of a positive phase III trial versus placebo. Bevacizumab is also indicated in the first-line treatment of metastatic RCC given in combination with interferon-α as a consequence of two positive phase III trials. Temsirolimus, unlike the other agents, has also shown activity in poor-prognosis patients, and is now the treatment of choice in previously untreated poor-prognosis RCC as a single agent. Everolimus can be considered as the best therapeutic option in patients with RCC pretreated with targeted agents as a consequence of a positive phase III study versus best supportive care. Markers for appropriate treatment selection, combined use of targeted agents, treatment of special histologies, and adjuvant and neoadjuvant setting represent important special issues to be dealt with in future studies. Anti-Cancer Drugs 20:893-900.

Original languageEnglish
Pages (from-to)893-900
Number of pages8
JournalAnti-Cancer Drugs
Volume20
Issue number10
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Renal Cell Carcinoma
Interferons
Therapeutics
Endothelial Growth Factors
Sirolimus
Immunotherapy
Histology
Placebos
Cytokines
Pharmaceutical Preparations

Keywords

  • Bevacizumab
  • Everolimus
  • Interferon-a
  • Renal cell carcinoma
  • Sorafenib
  • Sunitinib
  • Targeted therapies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Facchini, G., Perri, F., Caraglia, M., Pisano, C., Striano, S., Marra, L., ... Iaffaioli, R. V. (2009). New treatment approaches in renal cell carcinoma. Anti-Cancer Drugs, 20(10), 893-900. https://doi.org/10.1097/CAD.0b013e32833123d4

New treatment approaches in renal cell carcinoma. / Facchini, Gaetano; Perri, Francesco; Caraglia, Michele; Pisano, Carmela; Striano, Stefano; Marra, Luigi; Fiore, Francesco; Aprea, Pasquale; Pignata, Sandro; Iaffaioli, Rosario Vincenzo.

In: Anti-Cancer Drugs, Vol. 20, No. 10, 11.2009, p. 893-900.

Research output: Contribution to journalArticle

Facchini, Gaetano ; Perri, Francesco ; Caraglia, Michele ; Pisano, Carmela ; Striano, Stefano ; Marra, Luigi ; Fiore, Francesco ; Aprea, Pasquale ; Pignata, Sandro ; Iaffaioli, Rosario Vincenzo. / New treatment approaches in renal cell carcinoma. In: Anti-Cancer Drugs. 2009 ; Vol. 20, No. 10. pp. 893-900.
@article{5e7745f761574ebdbf12cb7551545e20,
title = "New treatment approaches in renal cell carcinoma",
abstract = "Metastatic renal cell carcinoma (RCC) is notoriously chemoresistant; up until recently, immunotherapy (in particular interferon-a) has represented the treatment of choice. The understanding of the biology of RCC has resulted in the development of targeted therapies. In particular, multikinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib), antivascular endothelial growth factor agents (bevacizumab), and mammalian target of rapamycin inhibitors (temsirolimus, everolimus) now have a role in the approach to different subsets of RCC. Sunitinib is indicated for the first-line therapy of metastatic RCC as a consequence of a positive phase III trial versus interferon-α; sorafenib is now registered for the second-line treatment of RCC, which was earlier treated with cytokine as a consequence of a positive phase III trial versus placebo. Bevacizumab is also indicated in the first-line treatment of metastatic RCC given in combination with interferon-α as a consequence of two positive phase III trials. Temsirolimus, unlike the other agents, has also shown activity in poor-prognosis patients, and is now the treatment of choice in previously untreated poor-prognosis RCC as a single agent. Everolimus can be considered as the best therapeutic option in patients with RCC pretreated with targeted agents as a consequence of a positive phase III study versus best supportive care. Markers for appropriate treatment selection, combined use of targeted agents, treatment of special histologies, and adjuvant and neoadjuvant setting represent important special issues to be dealt with in future studies. Anti-Cancer Drugs 20:893-900.",
keywords = "Bevacizumab, Everolimus, Interferon-a, Renal cell carcinoma, Sorafenib, Sunitinib, Targeted therapies",
author = "Gaetano Facchini and Francesco Perri and Michele Caraglia and Carmela Pisano and Stefano Striano and Luigi Marra and Francesco Fiore and Pasquale Aprea and Sandro Pignata and Iaffaioli, {Rosario Vincenzo}",
year = "2009",
month = "11",
doi = "10.1097/CAD.0b013e32833123d4",
language = "English",
volume = "20",
pages = "893--900",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - New treatment approaches in renal cell carcinoma

AU - Facchini, Gaetano

AU - Perri, Francesco

AU - Caraglia, Michele

AU - Pisano, Carmela

AU - Striano, Stefano

AU - Marra, Luigi

AU - Fiore, Francesco

AU - Aprea, Pasquale

AU - Pignata, Sandro

AU - Iaffaioli, Rosario Vincenzo

PY - 2009/11

Y1 - 2009/11

N2 - Metastatic renal cell carcinoma (RCC) is notoriously chemoresistant; up until recently, immunotherapy (in particular interferon-a) has represented the treatment of choice. The understanding of the biology of RCC has resulted in the development of targeted therapies. In particular, multikinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib), antivascular endothelial growth factor agents (bevacizumab), and mammalian target of rapamycin inhibitors (temsirolimus, everolimus) now have a role in the approach to different subsets of RCC. Sunitinib is indicated for the first-line therapy of metastatic RCC as a consequence of a positive phase III trial versus interferon-α; sorafenib is now registered for the second-line treatment of RCC, which was earlier treated with cytokine as a consequence of a positive phase III trial versus placebo. Bevacizumab is also indicated in the first-line treatment of metastatic RCC given in combination with interferon-α as a consequence of two positive phase III trials. Temsirolimus, unlike the other agents, has also shown activity in poor-prognosis patients, and is now the treatment of choice in previously untreated poor-prognosis RCC as a single agent. Everolimus can be considered as the best therapeutic option in patients with RCC pretreated with targeted agents as a consequence of a positive phase III study versus best supportive care. Markers for appropriate treatment selection, combined use of targeted agents, treatment of special histologies, and adjuvant and neoadjuvant setting represent important special issues to be dealt with in future studies. Anti-Cancer Drugs 20:893-900.

AB - Metastatic renal cell carcinoma (RCC) is notoriously chemoresistant; up until recently, immunotherapy (in particular interferon-a) has represented the treatment of choice. The understanding of the biology of RCC has resulted in the development of targeted therapies. In particular, multikinase inhibitors (sunitinib, sorafenib, axitinib, pazopanib), antivascular endothelial growth factor agents (bevacizumab), and mammalian target of rapamycin inhibitors (temsirolimus, everolimus) now have a role in the approach to different subsets of RCC. Sunitinib is indicated for the first-line therapy of metastatic RCC as a consequence of a positive phase III trial versus interferon-α; sorafenib is now registered for the second-line treatment of RCC, which was earlier treated with cytokine as a consequence of a positive phase III trial versus placebo. Bevacizumab is also indicated in the first-line treatment of metastatic RCC given in combination with interferon-α as a consequence of two positive phase III trials. Temsirolimus, unlike the other agents, has also shown activity in poor-prognosis patients, and is now the treatment of choice in previously untreated poor-prognosis RCC as a single agent. Everolimus can be considered as the best therapeutic option in patients with RCC pretreated with targeted agents as a consequence of a positive phase III study versus best supportive care. Markers for appropriate treatment selection, combined use of targeted agents, treatment of special histologies, and adjuvant and neoadjuvant setting represent important special issues to be dealt with in future studies. Anti-Cancer Drugs 20:893-900.

KW - Bevacizumab

KW - Everolimus

KW - Interferon-a

KW - Renal cell carcinoma

KW - Sorafenib

KW - Sunitinib

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=73349131053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349131053&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32833123d4

DO - 10.1097/CAD.0b013e32833123d4

M3 - Article

VL - 20

SP - 893

EP - 900

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 10

ER -